Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation

Tepotinib is a key drug for cancer patients with mesenchymal‐epithelial transition receptor tyrosine kinase proto‐oncogene (MET) exon 14 skipping mutation. However, its bioavailability in the cerebrospinal fluid (CSF) in humans has not been fully elucidated. Moreover, information about the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hisashi, Taima, Kageaki, Makiguchi, Tomonori, Nakagawa, Junichi, Niioka, Takenori, Tasaka, Sadatomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819565/
https://www.ncbi.nlm.nih.gov/pubmed/33387444
http://dx.doi.org/10.1002/cac2.12124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819565/
https://www.ncbi.nlm.nih.gov/pubmed/33387444
http://dx.doi.org/10.1002/cac2.12124

Ejemplares similares